|
|
Volumn 20, Issue 2, 2012, Pages 1060-1075
|
|
Novel (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: Peroxisome proliferator-activated receptor γ selective agonists with protein-tyrosine phosphatase 1B inhibition
a
a
a
a
a
a
a
a
a
|
|
Author keywords
Diabetes; Hemodilution; KK A y mouse; Peroxisome proliferators activated receptor agonist; Protein tyrosine phosphatase 1B inhibitor; SD rat; Tetrahydroisoquinoline derivative
|
|
Indexed keywords
1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLIC ACID DERIVATIVE;
2 [2 (1 ETHYLPROPEN 1 YL) 5 METHYLOXAZOL 4 YL]ETHYLMETHANESULFONATE;
2 [2 (3,3 DIMETHYLPENTEN 1 YL) 5 METHYLOXAZOL 4 YL]ETHYLMETHANESULFONATE;
2 [2 (4,4 DIMETHYLPENTEN 1 YL) 5 METHYLOXAZOL 4 YL]ETHYLMETHANESULFONATE;
2 [5 METHYL 2 (3,3 DIMETHYLBUTEN 1 YL)METHYLOXAZOL 4 YL]ETHYLMETHANESULFONATE;
2 [5 METHYL 2 (4 METHYLPENTEN 1 YL) 5 METHYLOXAZOL 4 YL]ETHYLMETHANESULFONATE;
2 [5 METHYL 2 (5 METHYLBUTEN 1 YL)OXAZOL 4 YL]ETHYLMETHANESULFONATE;
2 [HEXADIENOYL] 7 [2 [5 METHYL 2 (5 METHYLHEXEN 1 YL)OXAZOYL 4 YL]ETHOXY] 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLIC ACID;
2 METHYLPENTENAMIDE;
4,4 DIMETHYLHEXENAMIDE;
5 METHYLHEXENAMIDE;
5,5 DIMETHYLHEXENAMIDE;
GLUCOSE;
METHYL[2 (1 ETHYLPENTEN 1 YL) 5 METHYLOXAZOL 4 YL]ACETATE;
METHYL[2 (1 ETHYLPROPEN 1 YL) 5 METHYLOXAZOL 4 YL]ACETATE;
METHYL[2 (1,5 DIMETHYLHEXEN 1 YL) 5 METHYLOXAZOL 4 YL]ACETATE;
METHYL[2 (3,3 DIMETHYLPENTEN 1 YL) 5 METHYLOXAZOL 4 YL]ACETATE;
METHYL[2 (3,3 DIMETHYLPENTEN 1 YL)METHYLOXAZOL 4 YL]ACETATE;
METHYL[2 (4,4 DIMETHYLPENTEN 1 YL) 5 METHYLOXAZOL 4 YL]ACETATE;
METHYL[5 METHYL 2 (1 METHYLBUTEN 1 YL)OXAZOL 4 YL]ACETATE;
METHYL[5 METHYL 2 (1 METHYLPENTEN 1 YL)OXAZOL 4 YL]ACETATE;
METHYL[5 METHYL 2 (3 METHYLHEXEN 1 YL)OXAZOL 4 YL]ACETATE;
METHYL[5 METHYL 2 (5 METHYLHEXEN 1 YL)OXAZOL 4 YL]ACETATE;
METHYL[5 METHYL 2 (5 METHYLHEXYL)OXAZOL 4 YL]ACETATE;
NEW DRUG;
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST;
PROTEIN TYROSINE PHOSPHATASE 1B;
PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR;
ROSIGLITAZONE;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ARTICLE;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG POTENCY;
DRUG SAFETY;
DRUG STRUCTURE;
DRUG SYNTHESIS;
DRUG TARGETING;
ENZYME INHIBITION;
ERYTHROCYTE COUNT;
FEMALE;
GLUCOSE BLOOD LEVEL;
GLYCEMIC CONTROL;
HEMATOCRIT;
IC 50;
MAXIMUM PLASMA CONCENTRATION;
NONHUMAN;
RAT;
ADMINISTRATION, ORAL;
ANIMALS;
ENZYME ACTIVATION;
FEMALE;
HUMANS;
HYPOGLYCEMIC AGENTS;
ISOQUINOLINES;
MALE;
MICE;
OXAZOLES;
PPAR GAMMA;
PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1;
RATS;
RATS, SPRAGUE-DAWLEY;
STEREOISOMERISM;
STRUCTURE-ACTIVITY RELATIONSHIP;
TETRAHYDROISOQUINOLINES;
MUS;
RATTUS;
|
|
EID: 84855785936
PISSN: 09680896
EISSN: 14643391
Source Type: Journal
DOI: 10.1016/j.bmc.2011.11.035 Document Type: Article |
|
Times cited : (27)
|
|
References (31)
|
